1. 1. Amouei A, Asgharnia H, Fallah H, Faraji H, Barari R. Characteristics of Effluent Wastewater in Hospitals of Babol University of Medical Sciences, Babol, Iran, Health Scope 2015;4:e23222. [In Persian] [DOI:10.17795/jhealthscope-23222]

2. Farré M, Pérez S, Kantiani L, Barcelo D. Fate and toxicity of emerging pollutants, their metabolites and transformation products in aquatic environment. Sci Total Environ. 2008; 27: 991-1007. [DOI:10.1016/j.trac.2008.09.010]

3. Rowney NC, Johnson AC, Williams RJ. Cytotoxic drugs in drinking water: a prediction and risk assessment exercise for the thames catchment in the United kingdom. Environ Toxicol Chem. 2009;28:2733-43. [DOI:10.1897/09-067.1]

4. Kummerer K. Drugs in the environment: emission of drugs, diagnostic aids and disinfectants into wastewater by hospitals in relation to other sources. A review. Chemosphere 2001;45:957-969. [DOI:10.1016/S0045-6535(01)00144-8]

5. Aungst BJ. Novel formulation strategies for improving oral bioavailability of drugs with poor membrane permeation or presystemic metabolism. J Pharm Sci 1993;82:979-987. [DOI:10.1002/jps.2600821008]

6. Macpherson IRJ, Cassidy J. Challenges in combinational oncology studies. Pharm Med 2008;22:85-97. [DOI:10.1007/BF03256688]

7. Kortenkamp A, Faust M, Scholze M, Backhaus T. Low level exposure to multiple chemicals: reason for human health concerns? Environ Health Perspect 2007;115:106-114. [DOI:10.1289/ehp.9358]

8. Jones O, Voulvoulis N, Lester JN. Human pharmaceuticals in wastewater treatment processes. Crit Rev Environ Sci Technol 2005;35:401-427. [DOI:10.1080/10643380590956966]

9. Isidori M, Lavorgna M, Russo C, Kundi M, Žegura B, Novak M, et al. Chemical and toxicological characterisation of anticancer drugs in hospital and municipal wastewaters from Slovenia and Spain. Environ Pollut 2016;219:275-287. [DOI:10.1016/j.envpol.2016.10.039]

10. Fuerhacker M, Mahnik SN, Lenz K, Weissenbacher N, Mader RM, Krenn P, et al. Hospital waste water: health risk for human and environment by cytostatic drug emissions? Part I: model calculation and chemical monitoring. BMC Pharmacol 2007;7:A69. [DOI:10.1186/1471-2210-7-S2-A69]

11. Jaafari J, Dehghani MH, Hoseini M, Safari GH. Investigation of hospital solid waste management in Iran. World Rev Sci Technol Sustain Dev 2015;12:111-125. [DOI:10.1504/WRSTSD.2015.073820]

12. Chen M, Ohman K, Metcalfe C, Ikonomou M, Amatya P, Wilson J. Pharmaceuticals and endocrine disruptors in wastewater treatment effluents and in the water supply system of Calgary, Alberta, Canada. Water Qual Res J Can 2006;40:351-64. [DOI:10.2166/wqrj.2006.039]

13. Ebele AJ, Abdallah MA, Harrad S. Pharmaceuticals and personal care products (PPCPs) in the freshwater aquatic environment Emerg Contam 2017;3:1-16. [DOI:10.1016/j.emcon.2016.12.004]

14. Ghafuri Y, Yunesian M, Nabizadeh R, Mesdaghinia A, Dehghani MH, Alimohammadi M. Platinum cytotoxic drugs in the municipal wastewater and drinking water, a validation method and health risk assessment. Human Ecologi Risk Ass 2017;24:1-13. [DOI:10.1080/10807039.2017.1400372]

15. Johnson AC, Jurgens MD, Williams RJ, Kummerer K, Kortenkamp A, Sumpter JP. Do cytotoxic chemotherapy drugs discharged into rivers pose a risk to the environment and human health? An overview and UK case study. J Hydrol 2008;348:167-175. [DOI:10.1016/j.jhydrol.2007.09.054]

16. Jobling S, Williams RJ, Johnson AC, Taylor A, Gross-Sorokin M, Nolan M, et al. Predicted exposures to steroid estrogens in UK rivers correlate with widespread sexual disruption in wild fish populations. Environ Health Perspect 2006;114:32-39. [DOI:10.1289/ehp.8050]

17. Gross-Sorokin MY, Roast SD, Brighty GC. Assessment of Feminization of Male Fish in English Rivers by the Environment Agency of England and Wales. Environ Health Perspect. 2006;114:147-51. [DOI:10.1289/ehp.8068]

18. Söffker M, Tyler CR. Endocrine disrupting chemicals and sexual behaviors in fish--a critical review on effects and possible consequences. Crit Rev Toxicol 2012;42:653-68. [DOI:10.3109/10408444.2012.692114]

19. Nambirajan K, Muralidharan S, Roy AA, Manonmani S. Residues of diclofenac in tissues of vultures in India: a post-ban scenario. Arch Environ Contam Toxicol 2018;74:292-97. [DOI:10.1007/s00244-017-0480-z]

20. Oaks JL, Gilbert M, Virani MZ, Watson RT, Meteyer CU, Rideout BA, et al. Diclofenac residues as the cause of vulture population decline in Pakistan. Nature 2004;427:630-3. [DOI:10.1038/nature02317]

21. Buerge IJ, Buser HR, Poiger T, Müller MD. Occurrence and fate of the cytostatic drugs cyclophosphamide and ifosfamide in wastewater and surface waters. Environ Sci Technol 2006;40:7242-50. [DOI:10.1021/es0609405]

22. O'Keefe TL. Cytotoxic drug contamination in hospital and municipal wastewater and its transfer to surface water. Pharma-Cycle, Inc, Middletown, RI; 2011:11.

23. Parrella A, Lavorgna M, Criscuolo E, Russo C, Isidori M. Estrogenic activity and cytotoxicity of six anticancer drugs detected in water systems. Sci Total Environ 2014;485:216-222. [DOI:10.1016/j.scitotenv.2014.03.050]

24. Ghafuri Y, Nabizadeh R. Composition and quantity of cytotoxic waste from oncology wards: A survey of environmental characterization and source management of medical cytotoxic waste. Biosci Biotech Res Comm 2017;10: 438-44. [DOI:10.21786/bbrc/10.3/17]

25. Kümmerer K, Al-Ahmad A. Estimation of the cancer risk to humans resulting from the presence of cyclophosphamide and ifosfamide in surface water. Environ Sci Pollut Res Int 2010;17:486-96. [DOI:10.1007/s11356-009-0195-4]

26. Garcia-Ac A, Segura PA, Viglino L, Gagnon C, Sauvé S. Comparison of APPI, APCI and ESI for the LCMS/MS analysis of bezafibrate, cyclophosphamide, enalapril, methotrexate and orlistat in municipal wastewater. J Mass Spectrom 2011;46:383-90. [DOI:10.1002/jms.1904]

27. Steger-Hartmann T, Kümmerer K, Schecker J. Trace analysis of the anti-neoplastics ifosfamide and cyclophosphamide in sewage water by two step solid phase extraction and GC/MS. J Chromatogr 1996;A726:179-84. [DOI:10.1016/0021-9673(95)01063-7]

28. Ferrando-Climent L, Rodríguez-Mozaz S, Barcelo D. Incidence of anticancer drugs in an aquatic urban system: From hospital effluents through urban wastewater to natural environment. Environmental Pollution 2014;216-223. [DOI:10.1016/j.envpol.2014.07.002]

29. Lenz K, Koellensperger G, Hann S, Weissenbacher N, Mahnik SN, Fuerhacker M. Fate of cancerostatic platinum compounds in biological wastewater treatment of hospital effluents. Chemosphere 2007;69:1765-74. [DOI:10.1016/j.chemosphere.2007.05.062]

30. Vyas N, Turner A. Sewell G. Platinum-based anticancer drugs in waste waters of a major UK hospital and predicted concentrations in recipient surface waters. Sci Total Environ 2014;493:324-29. [DOI:10.1016/j.scitotenv.2014.05.127]

31. Negreira N, de Alda ML, Barceló D. Cytostatic drugs and metabolites in municipal and hospital wastewaters in Spain: Filtration, occurrence, and environmental risk. Sci Total Environ 2014;497-498:68-77. [DOI:10.1016/j.scitotenv.2014.07.101]

32. Yin J, Shao B, Zhang J, Li K. A preliminary study on the occurrence of cytostatic drugs in hospital effluents in Beijing, China. Bull Environ Contam Toxicol 2010;84:39-45. [DOI:10.1007/s00128-009-9884-4]

33. Mahnik SN, Lenz K, Weissenbacher N, Mader RM, Fuerhacker M. Fate of 5-fluorouracil, doxorubicin, epirubicin, and daunorubicin in hospital wastewater and their elimination by activated sludge and treatment in a membrane-bio-reactor system. Chemosphere 2007;66:30-37. [DOI:10.1016/j.chemosphere.2006.05.051]

34. Weissbrodt D, Kovalova L, Ort C, Pazhepurackel V, Moser R, Hollender J, et al. Mass flows of X-ray contrast media and cytostatics in hospital wastewater. Environ Sci Technol 2009;43:4810-7. [DOI:10.1021/es8036725]

35. Mullot JU, Karolak S, Fontova A, Huart B, Levi Y. Development and validation of a sensitive and selective method using GC/MS-MS for quantification of 5-fluorouracil in hospital wastewater. Anal Bioanal Chem 2009;394:2203-12. [DOI:10.1007/s00216-009-2902-x]

36. Sadeghi TS, Hashemian F, Afshar M. Exploring cytotoxic drugs residues in hospital effluents using high performance liquid chromatography [Dissertation]. Tehran: Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University; 2016. P.30-35 [In Persian]

37. Hashemian F, Majdi M, Mohammadpour N. Cytotoxic deactivator system for hospital effluents. 2012. IR Patent No: 74272. Approved by Invention Committee of MOH and National Pharmaceutical Research Network.

38. Kosjek T, Heath E. Occurrence, fate and determination of cytostatic pharmaceuticals in the environment. Trends Anal Chem 2011;30:1065-1087. [DOI:10.1016/j.trac.2011.04.007]

39. Mullot JU, Karolak S, Fontova A, Huart B, Levi Y. Development and validation of a sensitive and selective method using GC/MS-MS for quantification of 5-fluorouracil in hospital wastewater. Anal Bioanal Chem 2009;394:2203-12. [DOI:10.1007/s00216-009-2902-x]

40. Voigt K, Brüggemann R. Ranking of pharmaceuticals detected in the environment: aggregation and weighting procedures. Comb Chem High Throughput Screen 2008;11:770-82. [DOI:10.2174/138620708786734299]

41. Zounková R, Odráska P, Dolezalová L, Hilscherová K, Marsálek B, Bláha L. Ecotoxicity and genotoxicity assessment of cytostatic pharmaceuticals. Environ Toxicol Chem 2007;26:2208-14. [DOI:10.1897/07-137R.1]

42. Smital T, Terzic S, Zaja R, Senta I, Pivcevic B, Popovic M, et al. Assessment of toxicological profiles of the municipal wastewater effluents using chemical analyses and bioassays. Ecotoxicol Environ Saf 2011;74:844-51. [DOI:10.1016/j.ecoenv.2010.11.010]

43. Česen M, Kosjek T, Busetti F, Kompare B, Heath E. Human metabolites and transformation products of cylophosphamide and ifosfamide: analysis, occurrence and formation during abiotic treatments. Environ Sci Pollut Res Int 2016;23:11209-23. [DOI:10.1007/s11356-016-6321-1]

44. Souza DM, Reichert JF, Martins AF. A simultaneous determination of anti-cancer drugs in hospital effluent by DLLME HPLC-FLD, together with a risk assessment. Chemosphere 2018;201:178-188. [DOI:10.1016/j.chemosphere.2018.02.164]

45. Collier AC. Pharmaceutical contaminants in potable water: Potential concerns for pregnant women and children. Eco Health 2007; 4:164-171. [DOI:10.1007/s10393-007-0105-5]

46. Mone SM, Gillman MW, Miller TL, Herman EH, Lipshultz SE. Effects of environmental exposures on the cardiovascular system: Prenatal period through adolescence. Pediatrics 2004;113:1058-1069.

47. Chow EJ, Friedman DL, Yasui Y, Whitton JA, Stovall M, Robison LL, et al. Decreased adult height in survivors of childhood acute lymphoblastic leukemia: A report from the childhood cancer survivor study. J Pediatr 2007;150:370-75. [DOI:10.1016/j.jpeds.2006.11.036]

48. Kümmerer K, Haiß A, Schuster A, Hein A, Ebert I. Antineoplastic compounds in the environment-substances of special concern. Environ Sci Pollut Res Int 2016;23:14791-804. [DOI:10.1007/s11356-014-3902-8]

49. Rey RP, Padron AS, Leon LG, Pozo MM, Baluja C. Ozonation of cytostatics in water medium. Nitrogen bases. Ozone Sci Eng 1999;21:69-77. [DOI:10.1080/01919519908547260]

50. Zhang J, Chang VWC, Giannis A, Wang J-Y. Removal of cytostatic drugs from aquatic environment: A review. Sci Total Environ 2013;44: 281-298. [DOI:10.1016/j.scitotenv.2012.12.061]

51. Khodkar A, Khoram Nezhadian S, Pendashte A. A review on elimination methods of anti-cancer drugs from effluents. Proceedings of the first international congress on environment; 2016 Feb 20; Tehran, Iran.